Extracorporeal adsorption of anti-Factor VIII allo-antibodies on randomly functionalized polystyrene resins

被引:7
作者
Huguet, HC
Lasne, D
Rothschild, C
Siali, R
Jozefonvicz, J
机构
[1] Univ Paris 11, Fac Pharmaceut Sci, Chatenay Malabry, France
[2] Univ Paris 05, Fac Pharmaceut Sci, INSERM, U428, F-75270 Paris 06, France
[3] Hop Necker Enfants Malad, APHP, Hematol Lab, Paris, France
[4] Hop Necker Enfants Malad, APHP, Ctr Accueil & Traitement Hemophiles, Paris, France
[5] Therapol, St Denis, France
[6] Univ Paris 13, Inst Galilee, Lab Rech Macromol, F-93430 Villetaneuse, France
关键词
Anti-FVIII inhibitors; functionalized adsorbers; haemophilia A; immunoadsorption; extracorporeal circulation;
D O I
10.1160/TH03-07-0430
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The occurrence of anti-factor VIII (FVIII) alto-antibodies is a severe complication of the treatment of haemophilia A patients, leading to the inhibition of transfused FVIII activity. The effective elimination of these inhibitory antibodies plays a decisive role in the management of affected patients. To achieve this, immunoadsorption devices employing synthetic adsorbers, which selectively eliminate inhibitors, are of interest in the treatment strategy of haemophilia A patients with inhibitors. Adsorbers consisting of polystyrene-based beads substituted with sulphonate and L-tyrosyl methylester groups, which mimic part of epitope of FVIII molecule recognized by inhibitors, exhibit selective binding capacities towards anti-FVIII antibodies. The adsorption of FVIII inhibitors was investigated by simulating an extracorporeal circulation of haemophilic plasma over these functionalized resins. These innovative adsorbers are able to remove around 25% of anti-FVIII antibodies in 15 minutes depending on the plasma tested. Furthermore, they do not modify the amount of essential plasmatic proteins or residual immunoglobulins G. Experiments which were carried out using different plasmas with various inhibitor titres demonstrate a good reproducibility regarding the adsorption capacity of the synthetic resin. The characteristics of adsorption are similar on either native or regenerated resins. Both the purely synthetic nature of the resin and its easy processability demonstrate the real advantages over currently available protocols. This synthetic adsorber is a major technological advance in selective removal of FVIII inhibitory antibodies.
引用
收藏
页码:259 / 266
页数:8
相关论文
共 30 条
[1]   INHIBITORS IN HEMOPHILIA PATIENTS - CURRENT STATUS AND MANAGEMENT [J].
ALEDORT, L .
AMERICAN JOURNAL OF HEMATOLOGY, 1994, 47 (03) :208-217
[2]   Polystyrene derivatives as candidates for extracorporeal adsorption of Factor VIII antibodies in the management of haemophiliac patients [J].
Boisson-Vidal, C ;
Haouam, M ;
Lakhiari, H ;
Huguet, H ;
Dahri, L ;
Sultan, Y ;
Jozefonvicz, J ;
Siali, R .
VOX SANGUINIS, 2002, 83 (03) :214-221
[3]  
Brackmann HH, 1999, HAEMOPHILIA, V5, P203
[4]   A blinded in vitro study with Refacto® mock plasma samples:: similar FVIII results between the chromogenic assay and a one-stage assay when using a higher cephalin dilution [J].
Caron, C ;
Dautzenberg, MD ;
Delahousse, B ;
Droulle, C ;
Pouzol, P ;
Dubanchet, A ;
Rothschild, C .
HAEMOPHILIA, 2002, 8 (05) :639-643
[5]  
CLAUSS A., 1957, ACTA HAEMATOL, V17, P237
[6]   Adsorption of immunoglobulin G and anti-Factor VIII inhibitory antibody from haemophiliac plasma to derivatized polystyrenes [J].
Cornelius, RM ;
Dahri, L ;
BoissonVidal, C ;
Muller, D ;
Jozefonvicz, J ;
Brash, JL .
BIOMATERIALS, 1997, 18 (05) :429-436
[7]  
DAHRI L, 1994, J BIOMAT SCI-POLYM E, V6, P695
[8]   SYNTHETIC SORBENTS FOR REMOVAL OF FACTOR-VIII INHIBITORS FROM HEMOPHILIC-A PLASMA [J].
DAHRI, L ;
BOISSONVIDAL, C ;
REGNAULT, V ;
MULLER, D ;
SULTAN, Y ;
STOLTZ, JF .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1995, 664 (01) :47-54
[9]   Extracorporeal immunoadsorption for the treatment of haemophilic patients with inhibitors to factor VIII or IX [J].
Derfler, K .
VOX SANGUINIS, 1999, 77 :57-64
[10]  
DiMichele DM, 2002, THROMB HAEMOSTASIS, V87, P52